Form 4: PALI CEO Finley Reports RSU Vesting, Tax-Related Stock Sale

Palisade Bio CEO John David Finley reported the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations.

Summary

• CEO John David Finley acquired 13,333 shares of Palisade Bio common stock on February 11, 2026, through the settlement of vested Restricted Stock Units (RSUs) granted on February 11, 2025.
• Finley sold 3,896 shares of common stock at $1.75 per share on February 12, 2026, to cover tax withholding obligations related to the RSU vesting.
• Following these transactions, Finley directly owns 27,353 shares and indirectly owns 51 shares through FCW Investments, LLC.
• Finley also holds 26,667 Restricted Stock Units, which are scheduled to vest in three equal annual installments starting February 11, 2026.
• The reported beneficial ownership includes 4,444 shares acquired under the Issuer's Employee Stock Purchase Plan on November 20, 2025.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event. While there's a sale of shares, it's for tax purposes, and the underlying RSU vesting and prior ESPP acquisition indicate continued executive alignment and investment in the company.

Positives

• Vesting of 13,333 Restricted Stock Units indicates continued compensation and alignment of management interests with shareholders.
• Acquisition of 4,444 shares under the Employee Stock Purchase Plan on November 20, 2025, demonstrates ongoing investment by the CEO in the company.

Negatives

• Sale of 3,896 shares, although for tax withholding, reduces the CEO's direct ownership in the company.

Future Outlook

The remaining 26,667 Restricted Stock Units held by John David Finley are scheduled to vest in three equal annual installments beginning on February 11, 2026, contingent on his continuous service to the Issuer.

Industry Context

StockSavvy.ai notes that insider transactions, particularly those involving RSU vesting and subsequent tax-related sales, are common occurrences in the biotech industry. While the sale reduces direct holdings, the underlying RSU vesting demonstrates continued compensation and retention of key executives, which is crucial for companies like Palisade Bio that rely heavily on leadership for strategic direction and R&D.

Comparison to Industry Standards

• Insider sales to cover tax obligations upon RSU vesting are standard practice across industries, including biotech. For example, executives at companies like Amgen or Gilead Sciences frequently execute similar transactions.
• The sale of 3,896 shares at $1.75 is a relatively small portion of the total shares acquired through vesting (13,333 shares), suggesting the primary intent was tax management rather than a significant reduction in exposure.

Related Party Transactions

• The reporting person is the managing member of FCW Investments, LLC, which indirectly holds 51 shares of common stock, and has sole investment and voting power over these securities.

Stakeholder Impact

• Shareholders: The vesting of RSUs and the CEO's continued holdings align management's interests with shareholders. The tax-related sale is a common practice and not indicative of a lack of confidence.
• Employees: The mention of the Employee Stock Purchase Plan (ESPP) and RSU grants highlights ongoing employee incentive programs.

Next Steps

• Future vesting of the remaining 26,667 Restricted Stock Units in three equal annual installments starting February 11, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions related to executive compensation, specifically the vesting of Restricted Stock Units and a subsequent sale of shares to cover tax obligations. Such transactions are common and generally do not signal a significant change in the company's fundamentals or the executive's long-term outlook. The CEO continues to hold a substantial number of shares and RSUs, indicating ongoing alignment with shareholder interests. Therefore, the filing itself does not provide a strong basis for a "buy" or "sell" recommendation, leading to a "hold" stance as it's a neutral event.

Keywords

Palisade Bio, PALI, John David Finley, Form 4, Insider Trading, Restricted Stock Units, RSU, Stock Sale, CEO, CFO, Beneficial Ownership, Employee Stock Purchase Plan